How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Elijah E. Cummings Lower Drug Costs Now Act
Client: WE WORK FOR HEALTH · Firm: THE STRATEGY GROUP, INC.
HR3 Lower Drug Cost legislation, advocacy to protect patient access
Elijah E. Cummings Lower Drug Costs Now Act
Client: WE WORK FOR HEALTH · Firm: THE STRATEGY GROUP, INC.
HR3 Lower Drug Cost legislation, advocacy to protect patient access
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
WE WORK FOR HEALTH via THE STRATEGY GROUP, INC.
2026 · third_quarter · Q3
Patient centered reforms of the Pharmacy Benefit Manager industry and Most Favored Nation policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via THE STRATEGY GROUP, INC.
2026 · second_quarter · Q2
Source: Senate LDA
Elijah E. Cummings Lower Drug Costs Now Act
Client: WE WORK FOR HEALTH · Firm: THE STRATEGY GROUP, INC.
HR3 Lower Drug Cost legislation, advocacy to protect patient access
HR3 Lower Drug Costs Now Act
Patent Reform, HR 9 The Innovation Act.
Patent Reform, HR 9 The Innovation Act.
Patent Reform, HR 9 The Innovation Act.
Patent Reform, HR 9 The Innovation Act.
Patient centered reforms of the Pharmacy Benefit Manager industry and Most Favored Nation policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via THE STRATEGY GROUP, INC.
2026 · first_quarter · Q1
Patient centered reforms of the Pharmacy Benefit Manager industry and Most Favored Nation policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via THE STRATEGY GROUP, INC.
2025 · fourth_quarter · Q4
Patient centered reforms of the Pharmacy Benefit Manager industry and Most Favored Nation policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via THE STRATEGY GROUP, INC.
2025 · third_quarter · Q3
Patient centered reforms of the Pharmacy Benefit Manager industry and Most Favored Nation policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via THE STRATEGY GROUP, INC.
2025 · second_quarter · Q2
Patient centered reforms of the Pharmacy Benefit Manager industry and Most Favored Nation policies
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via THE STRATEGY GROUP, INC.
2025 · first_quarter · Q1
Patient centered reforms of the Pharmacy Benefit Manager industry and the Inflation Reduction Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via THE STRATEGY GROUP, INC.
2024 · fourth_quarter · Q4
Patient centered reforms of the Pharmacy Benefit Manager industry, concerns with the Inflation Reduction Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via THE STRATEGY GROUP, INC.
2024 · third_quarter · Q3
Patient centered reforms of the Pharmacy Benefit Manager industry, concerns with the Inflation Reduction Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via THE STRATEGY GROUP, INC.
2024 · second_quarter · Q2
Patient centered reforms of the Pharmacy Benefit Manager industry, concerns with the Inflation Reduction Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via THE STRATEGY GROUP, INC.
2024 · first_quarter · Q1
Patient centered reforms of the Pharmacy Benefit Manager industry, Concerns with the Inflation Reduction Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via THE STRATEGY GROUP, INC.
2023 · fourth_quarter · Q4
Patient centered reforms of the Pharmacy Benefit Manager industry, Concerns with the Inflation Reduction Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via THE STRATEGY GROUP, INC.
2023 · third_quarter · Q3
Patient centered reforms of the Pharmacy Benefit Manager industry
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via THE STRATEGY GROUP, INC.
2022 · third_quarter · Q3
PDUFA reauthorization
Advocacy to protect patient access
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via THE STRATEGY GROUP, INC.
2022 · second_quarter · Q2
PDUFA reauthorization
Advocacy to protect patient access
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via THE STRATEGY GROUP, INC.
2022 · first_quarter · Q1
HR3 Lower Drug Cost legislation, advocacy to protect patient access
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via THE STRATEGY GROUP, INC.
2021 · fourth_quarter · Q4
HR3 Lower Drug Cost legislation, advocacy to protect patient access
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via THE STRATEGY GROUP, INC.
2021 · third_quarter · Q3
HR3 Lower Drug Cost legislation, advocacy to protect patient access
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
WE WORK FOR HEALTH via THE STRATEGY GROUP, INC.
2021 · third_quarter · RR
Prescription drug coverage, biopharma innovation
PHRMA via THE STRATEGY GROUP, INC.
2021 · second_quarter · Q2
HR3 Lower Drug Costs Now Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via THE STRATEGY GROUP, INC.
2021 · first_quarter · Q1
Maintain coverage of Medicare's Six Protected Classes
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via THE STRATEGY GROUP, INC.
2020 · fourth_quarter · Q4
Most Favored Nation/International Pricing Index
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via THE STRATEGY GROUP, INC.
2020 · third_quarter · Q3
Most Favored Nation/International Pricing Index
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via THE STRATEGY GROUP, INC.
2020 · second_quarter · Q2
Notice of Benefit and Payment Parameters
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via THE STRATEGY GROUP, INC.
2020 · first_quarter · Q1
Rebate Reform, International Pricing Index
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via THE STRATEGY GROUP, INC.
2019 · fourth_quarter · Q4
Rebate Reform, International Pricing Index
USMCA
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via THE STRATEGY GROUP, INC.
2019 · third_quarter · Q3
Rebate Reform, International Pricing Index
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via THE STRATEGY GROUP, INC.
2019 · second_quarter · Q2
Rebate Reform, International Pricing Index
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via THE STRATEGY GROUP, INC.
2019 · first_quarter · Q1
6 Protected Classes and Rebate Reform
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via THE STRATEGY GROUP, INC.
2018 · fourth_quarter · Q4
Medicare Part D, Medicare Part B
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via THE STRATEGY GROUP, INC.
2018 · third_quarter · Q3
Medicare Part D
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via THE STRATEGY GROUP, INC.
2018 · second_quarter · Q2
Medicare Part B, Medicare Part D
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via THE STRATEGY GROUP, INC.
2018 · first_quarter · Q1
Independent Payment Advisory Board, Centers for Medicare & Medicaid Services, Children's Health Insurance Program
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via THE STRATEGY GROUP, INC.
2017 · first_quarter · 1A
NIH Funding
Importation
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via THE STRATEGY GROUP, INC.
2017 · fourth_quarter · Q4
Independent Payment Advisory Board, Centers for Medicare & Medicaid Services
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via THE STRATEGY GROUP, INC.
2017 · third_quarter · Q3
Independent Payment Advisory Board, Centers for Medicare & Medicaid Services, Part D Low Income Subsidy
Re-authorization of the Prescription Drug User Fee Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via THE STRATEGY GROUP, INC.
2017 · second_quarter · Q2
Importation, Independent Payment Advisory Board
Re-authorization of the Prescription Drug User Fee Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via THE STRATEGY GROUP, INC.
2017 · first_quarter · Q1
Importation
NIH Funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via THE STRATEGY GROUP, INC.
2016 · fourth_quarter · Q4
NIH Funding
Medicare Part D and Part B
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via THE STRATEGY GROUP, INC.
2016 · third_quarter · Q3
NIH Funding
Medicare Part D and Part B
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via THE STRATEGY GROUP, INC.
2016 · second_quarter · Q2
Medicare Part D and Part B
NIH Funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via THE STRATEGY GROUP, INC.
2016 · first_quarter · Q1
Medicare Part D and Part B
NIH Funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via THE STRATEGY GROUP, INC.
2015 · fourth_quarter · Q4
Patent Reform, HR 9 The Innovation Act.
Medicare Part D
NIH Funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via THE STRATEGY GROUP, INC.
2015 · third_quarter · 3A
NIH Funding
Patent Reform, HR 9 The Innovation Act.
Medicare Part D and the Independent Payment Advisory Board
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via THE STRATEGY GROUP, INC.
2015 · third_quarter · Q3
NIH Funding
Medicare Part D and the Independent Payment Advisory Board
Patent Reform, HR 9 The Innovation Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via THE STRATEGY GROUP, INC.
2015 · second_quarter · Q2
Medicare Part D and the Independent Payment Advisory Board
Patent Reform, HR 9 The Innovation Act.
NIH Funding
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PHRMA via THE STRATEGY GROUP, INC.
2015 · second_quarter · RR
Medicare Part D, 340B Pharmacy, Patent Reform, IPAB, NIH funding
Medicare Part D, 340B Pharmacy, Patent Reform, IPAB, NIH funding
Medicare Part D, 340B Pharmacy, Patent Reform, IPAB, NIH funding